Nivolumab: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Immune checkpoint inhibitor targeting PD-1 * Indicated for melanoma, NSCLC, SCLC, RCC, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma * Not particularly immunosuppressive * May increase risk of routine bacterial infections (including C. difficile), fungal infections (aspergillosis, pneumocystis, candidemia), viral infections (V..." |
(No difference)
|
Latest revision as of 14:13, 17 July 2023
- Immune checkpoint inhibitor targeting PD-1
- Indicated for melanoma, NSCLC, SCLC, RCC, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma
- Not particularly immunosuppressive
- May increase risk of routine bacterial infections (including C. difficile), fungal infections (aspergillosis, pneumocystis, candidemia), viral infections (VZV, CMV, EBV)
